Skip to main content
. Author manuscript; available in PMC: 2020 Oct 29.
Published in final edited form as: Clin Cancer Res. 2017 Mar 22;23(15):4163–4169. doi: 10.1158/1078-0432.CCR-16-2658

Figure 2. Pharmacodynamic assays for apoptosis and DRD2 antagonism.

Figure 2

(A) M30 assay ratio in dose escalation patients who experienced induction over baseline (n=2 per sample). (B) Maximum versus baseline serum prolactin levels in dose-escalation cohort of patients.